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Purpose: To report an alternative treatment for metastatic tumors within the eye. 
Case Report: Five intravitreal injections of bevacizumab (2.5 mg each) were performed 
in one eye of a 50-year-old woman with choroidal metastasis of lung carcinoma. 
Tumor size was reduced, pain disappeared, vision improved, and there were no 
secondary reactions. Vision improved from 20/40 to 20/20 and metamorphopsia 
decreased. Ten months after initiating treatment, an ultrasonographic study revealed 
no residual tumor, the choroid was normal in thickness and fluorescein angiography 
revealed a scar but no mass lesion. 
Conclusion: Intravitreal bevacizumab displayed beneficial effects in reducing tumor 
size and improving symptoms in this case of choroidal metastasis of lung carcinoma. 
The antineoplasic properties of this agent make it a viable alternative for treatment 
of metastatic choroidal tumors. 
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INTRODuCTION
Metastatic choroidal tumors are the most 
common intraocular malignancy in adults 
of whom 50% to 70% are women. In female 
subjects, the primary tumor is in the breast in 
70% to 80% of cases while lung cancer accounts 
for another 10%. In male subjects, lung cancer 
account for 40% to 60% of cases.1,2 
Treatment for choroidal metastasis is 
based on the degree of activity and location 
of the primary tumor. If the patient is under 
systemic chemotherapy and the ocular tumor 
is asymptomatic, no ocular treatment is 
indicated. Treatment is recommended if the 
metastasis is threatening vision or the globe 
despite chemotherapy. In such cases, external 
beam radiation therapy or plaque radiotherapy 
and proton beam irradiation have been 
recommended.2,3
Bevacizumab is a humanized recombinant 
monoclonal antibody which targets the vascular 
endothelial growth factor (VEGF). VEGF is 
expressed in high levels in certain tumors. In 
2004, bevacizumab was approved by the US 
Food and Drug Administration for metastatic 
colon cancer, and two years later for use in lung 
cancer.4 In ophthalmology, it has been widely 
used as an intravitreal agent for treatment of 
proliferative (neovascular) eye diseases.5,6
There have been a number of reports on 
anti-angiogenic therapy for ocular tumors.7,8 
Intraocular bevacizumab has also been used 
in osteomas with neovascular membranes.9 IVB for Choroidal Metastasis; Sanchez de la Barquera and Cano
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Due to these reports and the fact that there 
are limited treatment options, we considered 
the use of bevacizumab as a valid alternative.
Herein we present a patient with metastatic 
choroidal carcinoma originating from the 
lung who received treatment with intravitreal 
bevacizumab (IVB) resulting in significant 
subjective and objective improvement.
CASE REPORT 
A 50-year-old woman with history of non-small 
cell lung carcinoma since November 2005, had 
been receiving chemotherapy with carboplatin, 
paclitaxel and systemic bevacizumab for 8 
months. She was referred on February 2007, 
due to loss of vision, accompanied with pain 
and metamorphopsia in her right eye. 
Vision was 20/40 in her right and 20/20 
in her left eye. Ophthalmoscopy revealed 
a subretinal mass, light orange in color 
approximately four disc diameters in size, 
temporal and superior to the fovea, without 
retinal detachment in the right eye (Fig. 1). 
Ultrasonography demonstrated a choroidal mass 
8.8×7.5 mm at its base with maximal elevation 
of 1.74 mm in the right eye (Fig. 2). Fluorescein 
angiography showed a mottled pattern in the 
region of the tumor without leakage (Fig. 3).
We  injected  2.5 mg  bevacizumab 
intravitreally in the right eye of the patient 
five times over a period of seven months. 
Table 1 shows the date of each injection. 
Pain disappeared after the third injection, 
metamorphopsia decreased and vision improved 
to 20/20. Fundus examination revealed 
regression of the tumor (Fig. 4). On January 
2008, a B-scan was performed with special 
attention to the temporal aspect of the globe 
Injection Date (month/day/year)
No. 1 03/07/07
No. 2 04/11/07
No. 3 06/11/07
No. 4 08/15/07
No. 5 10/17/07
Table 1. Dates of bevacizumab injections
Figure 1.  Fundus  appearance  of  the  right  eye  before 
treatment (February 27, 2007); a solid subretinal tumor 
can  be  observed  superior  and  temporal  to  the  fovea 
(arrows).
Figure 3. Pretreatment angiography; a hyperfluorescent 
non-vascularized tumor can be seen as a mottled pattern 
without leakage (arrow).
Figure 2. Ultrasound scan of the same eye as in figure 
1  before  treatment  (March  9,  2007);  a  choroidal  mass 
8.8×7.5 mm  in  basal  dimensions  and  with  maximal 
elevation of 1.74 mm is apparent in the temporal aspect 
of the globe (arrow).IVB for Choroidal Metastasis; Sanchez de la Barquera and Cano
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and no tumor could be detected; in addition, 
the choroid was of normal thickness (Fig. 5). 
The angiogram showed a less hyperfluorescent 
plaque without leakage (Fig. 6).
DISCuSSION
Bevacizumab was initially developed to treat 
colon cancer due to its main action as an 
inhibitor of angiogenesis for newly formed 
tumor vessels. We used it in our patient, 
bearing this fact in mind. In our patient systemic 
chemotherapy was inadequate to control the 
ocular complications. Additional therapy with 
intraocular bevacizumab caused the tumor to 
contract and disappear together with resolution 
of pain. We believe that intravitreal bevacizumab 
acted directly on the metastasis.
There are some reports on this treatment 
modality describing favorable outcomes and 
they recommend this approach as a therapeutic 
alternative. Kwo et al10 reported a patient 
treated with IVB for choroidal metastasis of 
colorectal carcinoma. In other reports where 
the tumors had been benign, vision improved 
due to resolution of the accompanying serous 
retinal detachment.8,9 
More cases with further follow-up and 
controlled trials are necessary to determine 
the long-term effects of IVB for this particular 
indication. 
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